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Summary
Tuberculosis, a major health problem in developing countries, has reemerged in recent years in
many industrialized countries. The increased susceptibility of immunocompromised individuals
to tuberculosis, and many experimental studies indicate that T cell-mediated immunity plays
an important role in resistance. The lymphokine interferon y (IFN-y) is thought to be a principal
mediator of macrophage activation and resistance to intracellular pathogens. Mice have been
developed which fail to produce IFN-y (gko), because of a targeted disruption of the gene for
IFN-y. Upon infection with Mycobacterium tuberculosis, although they develop granulomas, gko
mice fail to produce reactive nitrogen intermediates and are unable to restrict the growth of
the bacilli. In contrast to control mice, gko mice exhibit heightened tissue necrosis and succumb
to a rapid and fatal course of tuberculosis that couldbe delayed, but not prevented, by treatment
with exogenous recombinant IFN-y.
T
uberculosis remains the largest cause of morbidity and
mortality in the world from a single infectious agent
(1). Immune mechanisms necessary for protection are poorly
understood, although studies involving animal models and
human infections have implicated T cells as an essential com-
ponent of the immune response to Mycobacterium tuberculosis.
The lymphokine IFN-y, produced primarily by T cells and
NK cells, has been shown to be an important mediator of
macrophage activation in controlling a number of intracel-
lularpathogens, including Leishmania major(2, 3), Leishmania
donovani (4, 5), and Listeria monocytogenes (6-8).
,
Abundant
IFN-y mRNA has been found in pleural tissues from tuber-
culous pleuritis patients (9) and in the lesions of the self-healing
form of leprosy (10) . Injection of recombinant IFN-y into
lesions in lepromatous leprosy patients resulted in the migra-
tion of large numbers of Th cells and monocytes to the site
of injection (11, 12) and a decrease in acid-fast bacilli (11).
T cells which adoptively transferred protection against a viru-
lent M. tuberculosis challenge produce IFN-y when stimulated
in vitro (13). We have tested directly the importanceofIFN-y
in resistance to M. tuberculosis infection using a genetic
"knockout" mouse in which the single gene encoding IFN-y
was disrupted (14). Mice homozygous for the targeted IFN-y
gene disruption (gko) produce no IFN-y, but are healthy
in the absence of pathogens and appear not to have obvious
alterations in splenic or thymic cell populations. However,
in vitro activation of macrophages from gko mice was greatly
reduced and the ability of the mice to survive a BCG vaccine




Littermates from heterozygote (gko/+) breeding pairs
(Charles River Laboratories, Wilmington, MA) were genotyped
(14). All mice were maintained in a specific pathogen-free environ-
ment, and found to be free of all 12 mouse pathogens tested.
Bacterial Strains and Mouse Infections.
￿
Virulent M. tuberculosis
Erdman strain (Trudeau Institute, Saranac Lake, NY) was passed
through mice, and grown in culture once before storing in aliquots
at -70*C and titered. Before use, aliquots diluted in PBS con-
taining Tween 80 (0.5%) were briefly sonicated and 106 viable M.
tuberculosis was delivered intravenously.
Organ Harvesting.
￿
Organs retrieved from infected mice were
homogenized in PBSTween 80 (0.5%) in plastic bags using a
homogenizer (Stomacher; Tekmar Co., Cincinnati, OH), diluted,
and plated on supplemented 7H10 media(Difco Laboratories, Inc.,
Detroit, MI). Colonies were counted after 21 d incubation at 37°C.
Histology.
￿
Sections (5-Am) from paraffin blocks containinglung,
liver, and spleen were stained with hematoxylin and eosin, or by
the Ziehl-Neelsen method for acid-fast bacilli (AFB) .
Cytokine Assays.
￿
Spleen cells from M. tuberculosis-infected mice
were harvested 14 d after infection and stimulated with Con A
(5 ug/ml) or tuberculin purified protein derivative (PPD)(10 tag/ml).
Supernatants were collected after 72 h, filtered, and IFN-,y or IIA
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fectedMice. In aqueousphase, nitric oxide(NO) generatedby the
activation of the macrophage L-arginine-dependent mechanism
forms nitrite and nitrate. To assess RNI production, total serum
nitrite and nitrate concentrations were quantitated. Serum from
infected mice was pooled andfiltered (0.45 tim). Nitrate was con-
verted into nitrite using the Pseudomonas oleovorans nitrate reduc-
tase (15) by incubation of 20 ml serum with live P. oleovorans at
37°C for 2 h. Bacteria were removed by centrifugation and pro-
teinsprecipitated with 30% ZnS04. Total nitrite content was mea-
sured by the Greiss reaction, as previously described (16).
Reconstitution ofgkoMice with Exogenous IFN-y.
￿
Reconstitu-
tion doses were based on unpublished pharmacokinetic studies of
murine IFN--y performedby Sharon Chen (Genentech, Inc., South
San Francisco, CA).Micewere injected intramuscularly with 17,280
U of IFN-.y or PBS every third day for the length of the experi-
ment. Forcontinuous infusion, mice were subcutaneously implanted
with osmotic pumps (Alza Corp., Palo Alto, CA) delivering 4 U
IFN-,y/min or PBS.
Assessment ofIn Vivo TNF-a and Nitric Oxide Synthase (NOS)
mRNA Production. M. tuberculosis-infected mice were killed at 14 d
afterinfection. Spleen tissue wasfrozen in liquidnitrogen, and stored
at -70°C until use. RNA was extracted as previously described
(17). Anyresidual DNA was removed by treatment with DNase.
Reverse transcription reactions on 5 ltg total RNA were per-
formed using specific 3' primers or random hexamers, at 45°C,
for 1 h. PCR reactionswere performed on cDNA usingTNF-a-
specific primers (Stratagene, La Jolla, CA)or NOS-specific primers
(5' AATACGACTCACTATAGGGCTGTCAGAGCCTCGTGG-
CTTTGG, 3' ATTAACCCTCACTAAAGGGCCCTTCCGAAG-
TTTCTGGCAGCAGC) deducedfrom thepublishedsequence (18)
and the following conditions: at 94°C for 45 s, at 60°C for 45 s,
and at 72°C for 2 min for 30 cycles, and then at 72°C for 5 min.
Thereactions were electrophoresed on 2% agarose gels, transferred
to nitrocellulose, andprobed with a TNF-a or NOS-specific frag-
ment amplifiedfrom RNA from the murine macrophage cell line
RAW264.7.
Results and Discussion
Course ofM . tuberculosis Infection in gko Mice
￿
Gkoand wild-
type (+/+)littermates were infected intravenously with viru-
lent M . tuberculosis (106, Erdman strain). The mean survival
time for M . tuberculosis-infected gko mice was 15 ± 1 d, com-
pared with >60 d for +/+ littermate controls (Fig. 1), at
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M. tuberculosis CFU recovered from organs of infected gko
(-40-) and +/+ (-4---) mice. Data shown arecombined data from three
separate experiments. Error bars, SE.
infection, 10-100-fold more viable bacteria were found in the
organs of gko mice compared with +/+ controls (Fig. 2) .
Histopathological examination of the mice revealed striking
differences betweengko and +/+ mice. Although both +/+
and gko mice formed granulomas upon infection, by 14 d
after infection -90% of the granulomas in the liver and20%
in the lungs of the gko mice were necrotic and contained
apparently extracellular AFB (Fig. 3, A and C). The spleens
Figure 1.
￿
Survival curves ofmice infected with M. tuber-
culosis. (A)gko (0)and +/+ (")littermates were infected
intravenously with 106 M. tuberculosis strain Erdman. Data
presented are from three separate experiments, and repre-
sent 18 mice in each group. p = < .0001 in paired Stu-
dent's t test. (B) gko mice were implanted subcutaneously
with Alzet osmotic pumps loaded with IFN-.y (104 U/h)
(0) or PBS (0), and infected as above. Infected +/+ lit-
termates (")were used as controls. Each group represents
sixmice. p = .0036forPBSandIFN-.y-treated gko mice.from gko mice were consumed by large necrotizing granu-
lomas filled with AFB, with much of the tissue destroyed
(Fig. 3 E) . Necrosis was not seen in any of the organs from
either +/+ or +/- mice . The survival curves, together with
theCFU and histological data, indicate that IFN-y is a lym-
phokine essential to the survival of mice infected withM.
tuberculosis. Necrosis, which is generally not observed in im-
munocompetent mice, but is observed in human tuberculous
infections, may be the consequence of the products of the
increased bacterial load in gko mice, or of the immune re-
sponse, e.g., possible overproduction of TNF-ci in the in-
fected mice, or both .
Reconstitution ofgko Mice with Exogenously Added IFN-y .
Since the defect in the gko mice was a genetically defined
one, the possibility of reconstituting immune function by
exogenous recombinant lymphokine was investigated . It was
reported previously that a relatively susceptible strain of mice,
BALB/c, when infected withM . tuberculosis, exhibited increased
survival if infused with IFN-y, compared with BALB/c mice
given heat-inactivated cytokine (19) . We attempted reconsti-
tution ofgko mice by either of two methods : intramuscular
injections ofIFN-y or continuous infusion via surgically im-
planted osmotic pumps . Mice were infected withM. tubercu-
losis 2 d after initiation ofIFN-y treatment . When IFN-y
was given by injection, the gko mice survived 4 d longer
on average than gko mice treated with PBS (19 ± 0.7 vs
15 ± 0.3 d,p = <.0001), and there was a 10-100-fold de-
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Figure 3 . Histology sections . Mice were
killed 2 wk after infection and formalin-fixed
sections were stained for AFB using the Ziehl-
Neelsen method. Mycobacteria stain red,
whereas tissues stain blue. (A) Liver, gko, and
necrotic granulomas (x140); (B) liver, +/+
(x 140) ; (C) lung, gko (x70) ; (D) lung, +/+
( x 70) ; (E) spleen, gko, with extensive necrosis
(x 70) ; and (F) spleen, +/+ (x70) .
crease in the number of bacilli recovered from the lungs and
livers, respectively, in the IFN-y-treated mice, compared with
the PBS-treated mice at 14 d after infection (lungmean CFU
5.2 ± 3.5 x 106 vs 5 .1 ± 3.1 x 107 ; liver mean CFU
3.8 ± 2.7 x 106 vs 1.9 ± 0.1 x 108) . All control mice
(+/+ and +/- littermates) survived the infection, and ad-
ministration of IFN-y had no effect on the numbers ofbacilli
recovered from the organs of these mice. When reconstitu-
tion was attempted using implantable osmoticpumps to de-
liver IFN-y or PBS, a 12 d increase in average survival time
was seen in gko mice treated with IFN-y compared with
PBS-treated mice (28 ± 2.5 vs 16 ± 0.4 d, p = .003) (Fig.
1), again with a significant decrease in numbers ofbacilli re-
covered from the organs of IFN-y-infused mice at 14 d after
infection (lung mean CFU 3.1 ± 1.6 x 106 VS 1.6 ±
0.7 x 10 7 ; liver mean CFU 3.0 ± 0.1 x 106 vs 3.3 ± 0.9
x 108 ) . Histological samples from this time point showed
extensive necrosis with large numbers of AFB in the liver
and spleen of PBS-infused gko mice, whereas the IFN-y-
infused gko mice did not exhibit necrosis .
Thus, exogenously added IFN-y reduced the bacterial load
and increased survival of gko mice, demonstrating the im-
portance ofIFN-y in theimmune response toM. tuberculosis.
Nevertheless, treatment with exogenous IFN-y was unable
to reconstitute fully protective immune function and prevent
mortality of gko mice using this challenge dose. Although
the reconstitution conditions tested were very limited, anumber of possibilities for this outcome require considera-
tion . Since the circulating half-life of administered IFN-y in
mice is -1 h (Chen, S ., personal communication), it is un-
clear whether the IFN-y was available in effective concentra-
tions, especially in the granulomas . The increased survival
of the mice receiving continuous IFN-y infusion vs IFN-y
injections supports the view that the inability to fully recon-
stitute the IFN-y defectmay largely be a problem of delivery
and bioavailability. It is also possible that the absence of IFN-y
in gko mice has a regulatory effect on the expression of other
cytokines that are necessary to controlM. tuberculosis infec-
tion, although no differences in the expression levels ofTNF-a,
another cytokine involved in macrophage activation, in gko
mice compared with +/+ mice were observed (Fig. 4, and
our unpublished results) . Finally, since exogenous IFN-y
significantly reduced the number of bacilli recovered from
the mice, which probably accounts for the increased time of
survival, more dramatic effects might be seen at lower M .
tuberculosis challenge doses .
To examine the T cell cytokine profiles from gko mice,
spleens fromM. tuberculosis-infected gko and +/+ mice were
stimulated in vitro with ConA or tuberculinPPD. Although
splenocytes from all mice tested proliferated to the antigens,
only +/+ mice produced IFN-y (>200 ng/ml with both
antigens), whereas gko mice failed to produce any detectable
IFN-y when stimulated with either antigen (<25 pg/ml) .
Of interest, the lack ofIFN-y did not result in a discernible
increase in T cells producing IL-4, as IL-4 production was
low but indistinguishable between the strains .
In Vivo Production ofRNIfromM. tuberculosis-infected gko
Mice Is Greatly Reduced. Macrophage activation is consid-
ered essential to the resolution ofM. tuberculosis infection .
We and others (16, 19, 20) have previously reported that NO,
and its related RNI, are responsible for destruction ofviru-
lent tubercle bacilli by murine macrophages, a response that
requires treatment in vitro with both IFN-y and TNF-a .
Consequently, we examined the in vivo production ofRNI
in these mice. It was reported previously that peritoneal mac-
rophages recovered from BCG-infected gko mice required the
addition of exogenous IFN-y to generate RNI in vitro (14) .
At 8 d after infection withM . tuberculosis, neither gko nor
+/+ mice had measurable levels of RNI in their sera, nor
was it possible to detect RNI in the sera of uninfected gko
Figure 4 .
￿
In vivo expression of TNF-a (A) andNOS (B) mRNA in
M tuberculosis-infected mice using RNA-PCR . Gko mice (-/-) were
treated with PBS or IFN-y via osmoticpump . +/+ are littermate control
mice . IFN-y stimulatedRAW264 .7 cells were used as a source ofcontrol
RNA (M0) . Control PCR reactions with /32-microglobulin and 0-actin
primers were performed (data not shown) .
Table 1 .
￿
RNI in Sera ofM . tuberculosis-infected
gko and +/+ mice
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gko plus M. tb
gko plus M. tb
+ / + plus M. tb
gko plus M. tb
gko plusM. tb
+ / + plus M . tb
Sera obtained from mice were treated to reduce N03 to N02, and N02
was measured by the Greiss reagent . 4 .5 uM was the lower limit of de-
tection in this assay . Experiment was repeated once, with similar results .
M. tb, M . tuberculosis .
or +/+ mice. However, at 14 d after infection, +/+ mice
showed high serum levels of RNI, comparable with those
of mice injected with LPS (21), whereas gko mice had very
low serum RNI levels (Table 1) . Production ofRNI in mice
infected with mycobacteria sharply increases at -10 d after
infection (15) (Chan, J., and B. R . Bloom, unpublished ob-
servation) .
The key enzyme involved in the production ofNO from
arginine, NOS, is produced by a number of cell types in the
mouse, including an inducible isoform in macrophages, the
gene for which has recently been cloned (18, 22, 23) . We
examined the in vivo levels ofNOSmRNA produced byM.
tuberculosis-infected gko and +/+ mice byRNA-PCR using
NOS-specific primers . NOS-specific mRNA was present in
the spleens of +/+ mice at 14 d after infection, but at con-
sistently lower or undetectable levels in spleens from gko mice
infused with PBS or IFN-y (Fig. 4) . In contrast, MRNA
for TNF-a, which is also produced by macrophages, was
present in +/+ as well as gko mice. The results from these
experiments indicated that in vivo gko mice make far less
RNI than wild-type controls, and are consistent with the
interpretation that production ofRNI, at least in the mu-
rine model, may be a necessary mechanism for the control
ofM . tuberculosis infection .
Findings in the gko model may have relevance to tubercu-
losis in AIDS . As CD4 function declines in HIV infection,
IFN-y production by T cells is reduced (24, 25), and the
pattern ofM. tuberculosis infection is frequently more diffuse
than that seen in classical tuberculosis, but characterized by
extensive tissue necrosis (26, 27) . There are some striking
similarities in the pattern of infection in the gko mouse : there
is greater bacterial growth and dissemination, and necrosis
particularly ofliver and spleen, relative to infection in +/+
control mice . Initial attempts to compensate for diminished











14 None 373.0sion ofexogenousIFN-y reducedbacillaryload andprolonged
survival of infected gkomice, but ultimately failed to protect
mice infected with a high challenge dose from death. The
implications are that effective lymphokine therapy, used as
a single agent, may be difficult to achieve in diseases such
as tuberculosis whichrequirelocalization oflymphokinesin
granulomas. However, IFN-y given in combinationwith ap-
propriate chemotherapy could contribute significantlyto reduc-
tion in bacillary numbers and prevention of dissemination.
Clearly, gko mice represent an extreme model in which the
host is unable to produce anyIFN-y necessary for activating
microbicidal activities. Thus, the therapeutic possibility of
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